Finance

Beta
Lists
ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$7.16
+0.56%
(+0.040) 1D
$7.16
0.00% (0.00)
After hours
Closed: Jun 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARCT...
Open
$7.28
High
$7.43
Low
$6.92
Mkt. cap
203.51M
Avg. vol.
440.13K
Volume
242.35K
52-wk high
$24.14
52-wk low
$5.86
EPS
-$2.82
Beta
2.36
Shares outstanding
28.42M
No. of employees
109
Open
$7.28
High
$7.43
Low
$6.92
Mkt. cap
203.51M
Avg. vol.
440.13K
Volume
242.35K
52-wk high
$24.14
52-wk low
$5.86
EPS
-$2.82
Beta
2.36
Shares outstanding
28.42M
No. of employees
109
Analyst outlook
Analyst Ratings
Based on 6 analysts giving stock ratings to ARCT in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12 month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ARCT in the last 3 months.
Highest
Current $7.16
$22.00 (+207.26%)
Average
$18.00 (+151.40%)
Lowest
$9.00 (+25.70%)
News stories
From sources across the web
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc
CEOJoseph E. Payne
Employees109
Founded2013
Headquarters-
SectorBiotechnology
Websitearcturusrx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
28.30M
17.15M
7.20M
2.06M
Cost of goods sold
29.58M
23.26M
24.48M
21.53M
Cost of revenue
29.58M
23.26M
24.48M
21.53M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.34M
10.40M
14.03M
9.46M
Operating expense
10.34M
10.40M
14.03M
9.46M
Total operating expenses
39.92M
33.66M
38.50M
30.99M
Operating income
-11.62M
-16.51M
-31.31M
-28.93M
Other non operating income
-
-
-
35.00K
EBT including unusual items
-9.18M
-13.45M
-29.08M
-26.96M
EBT excluding unusual items
-9.18M
-13.45M
-29.08M
-26.96M
Income tax expense
4.00K
-
-4.00K
-
Effective tax rate
-0.04%
-
0.01%
-
Other operating expenses
-
-
-
-
Net income
-9.18M
-13.45M
-29.08M
-26.96M
Net profit margin
-32.44%
-78.41%
-404.10%
-1,308.30%
Earnings per share
-0.34
-0.49
-1.03
-0.95
Interest and investment income
2.57M
3.23M
1.53M
1.93M
Interest expense
-
-
-9.00K
-
Net interest expenses
2.57M
3.23M
1.52M
1.93M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.84M
-15.75M
-30.62M
-28.27M
Gain or loss from assets sale
-
-
-
-34.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer